BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Noris M, Remuzzi G. Managing and preventing atypical hemolytic uremic syndrome recurrence after kidney transplantation. Curr Opin Nephrol Hypertens. 2013;22:704-712. [PMID: 24076560 DOI: 10.1097/mnh.0b013e328365b3fe] [Cited by in Crossref: 40] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Raina R, Sethi SK, Dragon-Durey MA, Khooblall A, Sharma D, Khandelwal P, Shapiro R, Boyer O, Yap HK, Bagga A, Licht C. Systematic review of atypical hemolytic uremic syndrome biomarkers. Pediatr Nephrol 2022. [PMID: 35118546 DOI: 10.1007/s00467-022-05451-2] [Reference Citation Analysis]
2 Raina R, Vijayvargiya N, Khooblall A, Melachuri M, Deshpande S, Sharma D, Mathur K, Arora M, Sethi SK, Sandhu S. Pediatric Atypical Hemolytic Uremic Syndrome Advances. Cells 2021;10:3580. [PMID: 34944087 DOI: 10.3390/cells10123580] [Reference Citation Analysis]
3 Brocklebank V, Johnson S, Sheerin TP, Marks SD, Gilbert RD, Tyerman K, Kinoshita M, Awan A, Kaur A, Webb N, Hegde S, Finlay E, Fitzpatrick M, Walsh PR, Wong EKS, Booth C, Kerecuk L, Salama AD, Almond M, Inward C, Goodship TH, Sheerin NS, Marchbank KJ, Kavanagh D. Factor H autoantibody is associated with atypical hemolytic uremic syndrome in children in the United Kingdom and Ireland. Kidney Int 2017;92:1261-71. [PMID: 28750931 DOI: 10.1016/j.kint.2017.04.028] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
4 Coppo R, Bonaudo R, Peruzzi RL, Amore A, Brunati A, Romagnoli R, Salizzoni M, Galbusera M, Gotti E, Daina E, Noris M, Remuzzi G. Liver transplantation for aHUS: still needed in the eculizumab era? Pediatr Nephrol. 2016;31:759-768. [PMID: 26604087 DOI: 10.1007/s00467-015-3278-0] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
5 Azukaitis K, Simkova E, Majid MA, Galiano M, Benz K, Amann K, Bockmeyer C, Gajjar R, Meyers KE, Cheong HI, Lange-Sperandio B, Jungraithmayr T, Frémeaux-Bacchi V, Bergmann C, Bereczki C, Miklaszewska M, Csuka D, Prohászka Z, Killen P, Gipson P, Sampson MG, Lemaire M, Schaefer F. The Phenotypic Spectrum of Nephropathies Associated with Mutations in Diacylglycerol Kinase ε. J Am Soc Nephrol 2017;28:3066-75. [PMID: 28526779 DOI: 10.1681/ASN.2017010031] [Cited by in Crossref: 28] [Cited by in F6Publishing: 13] [Article Influence: 5.6] [Reference Citation Analysis]
6 Santoro D, La Russa A, Toteda G, Perri A, Vizza D, Lupinacci S, Lofaro D, Pellicanò V, Granese R, Versaci A, Siligato R, Piccoli GB, Bonofiglio R. Identification of a New Complement Factor H Mutation in a Patient With Pregnancy-Related Acute Kidney Injury. Kidney Int Rep 2020;5:1603-7. [PMID: 32954088 DOI: 10.1016/j.ekir.2020.06.028] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Vilayur E, de Malmanche J, Trevillian P, Ferreira D. Metastatic lung adenocarcinoma- associated thrombotic microangiopathy in a renal transplant recipient. BMJ Case Rep 2018;11:e226707. [PMID: 30567242 DOI: 10.1136/bcr-2018-226707] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
8 Java A. Peri- and Post-operative Evaluation and Management of Atypical Hemolytic Uremic Syndrome (aHUS) in Kidney Transplantation. Adv Chronic Kidney Dis 2020;27:128-37. [PMID: 32553245 DOI: 10.1053/j.ackd.2019.11.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Brocklebank V, Kavanagh D. Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea. Clin Kidney J 2017;10:600-24. [PMID: 28980670 DOI: 10.1093/ckj/sfx081] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
10 Chua S, Wong G, Lim WH. The importance of genetic mutation screening to determine retransplantation following failed kidney allograft from recurrent atypical haemolytic ureamic syndrome. BMJ Case Rep. 2014;2014:pii: bcr2013202875. [PMID: 24671321 DOI: 10.1136/bcr-2013-202875] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
11 Mele C, Remuzzi G, Noris M. Hemolytic uremic syndrome. Semin Immunopathol 2014;36:399-420. [PMID: 24526222 DOI: 10.1007/s00281-014-0416-x] [Cited by in Crossref: 92] [Cited by in F6Publishing: 67] [Article Influence: 11.5] [Reference Citation Analysis]
12 Ávila A, Gavela E, Sancho A. Thrombotic Microangiopathy After Kidney Transplantation: An Underdiagnosed and Potentially Reversible Entity. Front Med (Lausanne) 2021;8:642864. [PMID: 33898482 DOI: 10.3389/fmed.2021.642864] [Reference Citation Analysis]
13 Portoles J, Huerta A, Arjona E, Gavela E, Agüera M, Jiménez C, Cavero T, Marrero D, Rodríguez de Córdoba S, Diekmann F; Matrix Investigators . Characteristics, management and outcomes of atypical haemolytic uraemic syndrome in kidney transplant patients: a retrospective national study. Clin Kidney J 2021;14:1173-80. [PMID: 33841863 DOI: 10.1093/ckj/sfaa096] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 de Andrade LGM, Contti MM, Nga HS, Bravin AM, Takase HM, Viero RM, da Silva TN, Chagas KN, Palma LMP. Long-term outcomes of the Atypical Hemolytic Uremic Syndrome after kidney transplantation treated with eculizumab as first choice. PLoS One 2017;12:e0188155. [PMID: 29136640 DOI: 10.1371/journal.pone.0188155] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
15 Palma LM, Langman CB. Critical appraisal of eculizumab for atypical hemolytic uremic syndrome. J Blood Med 2016;7:39-72. [PMID: 27110144 DOI: 10.2147/JBM.S36249] [Cited by in Crossref: 2] [Cited by in F6Publishing: 10] [Article Influence: 0.3] [Reference Citation Analysis]
16 Anders R, Grohmann M, Lindner TH, Bergmann C, Halbritter J. [Hemolytic kidney failure and transient ischemic attack in a 32-year-old female]. Internist (Berl) 2016;57:1022-8. [PMID: 27357251 DOI: 10.1007/s00108-016-0092-0] [Reference Citation Analysis]
17 Asif A, Nayer A, Haas CS. Atypical hemolytic uremic syndrome in the setting of complement-amplifying conditions: case reports and a review of the evidence for treatment with eculizumab. J Nephrol 2017;30:347-62. [PMID: 27848226 DOI: 10.1007/s40620-016-0357-7] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 7.2] [Reference Citation Analysis]
18 Abbas F, El Kossi M, Kim JJ, Sharma A, Halawa A. Thrombotic microangiopathy after renal transplantation: Current insights in de novo and recurrent disease. World J Transplantation 2018; 8(5): 122-141 [PMID: 30211021 DOI: 10.5500/wjt.v8.i5.122] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 8] [Article Influence: 4.8] [Reference Citation Analysis]
19 Sexton DJ, Reule S, Solid CA, Chen SC, Collins AJ, Foley RN. End-stage renal disease from hemolytic uremic syndrome in the United States, 1995-2010. Hemodial Int 2015;19:521-30. [PMID: 25689876 DOI: 10.1111/hdi.12281] [Reference Citation Analysis]
20 Raina R, Grewal MK, Radhakrishnan Y, Tatineni V, DeCoy M, Burke LL, Bagga A. Optimal management of atypical hemolytic uremic disease: challenges and solutions. Int J Nephrol Renovasc Dis 2019;12:183-204. [PMID: 31564951 DOI: 10.2147/IJNRD.S215370] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.7] [Reference Citation Analysis]
21 Garlo K, Dressel D, Savic M, Vella J. Successful eculizumab treatment of recurrent postpartum atypical hemolytic uremic syndrome after kidney transplantation. Clin Nephrol Case Stud 2015;3:8-13. [PMID: 29043127 DOI: 10.5414/CNCS108491] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
22 Münch J, Bachmann A, Grohmann M, Mayer C, Kirschfink M, Lindner TH, Bergmann C, Halbritter J. Effective immunosuppressive management with belatacept and eculizumab in post-transplant aHUS due to a homozygous deletion of CFHR1/CFHR3 and the presence of CFH antibodies. Clin Kidney J 2017;10:742-6. [PMID: 29225802 DOI: 10.1093/ckj/sfx053] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
23 Rodriguez-Osorio L, Ortiz A. Timing of eculizumab therapy for C3 glomerulonephritis. Clin Kidney J. 2015;8:449-452. [PMID: 26251715 DOI: 10.1093/ckj/sfv065] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
24 Mülling N, Rohn H, Vogel U, Claus H, Wilde B, Eisenberger U, Kribben A, Witzke O, Gäckler A. Low efficacy of vaccination against serogroup B meningococci in patients with atypical hemolytic uremic syndrome. Biosci Rep 2020;40:BSR20200177. [PMID: 32159209 DOI: 10.1042/BSR20200177] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Salvadori M, Bertoni E. Complement related kidney diseases: Recurrence after transplantation. World J Transplant 2016; 6(4): 632-645 [PMID: 28058212 DOI: 10.5500/wjt.v6.i4.632] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
26 Nunius C, Büttner-Herold M, Bertz S, Schiffer M, Buchholz B. Isolated thrombotic microangiopathy of the small intestine in a patient with atypical hemolytic uremic syndrome - a case report. BMC Nephrol 2020;21:104. [PMID: 32204691 DOI: 10.1186/s12882-020-01766-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
27 Grisaru S. Management of hemolytic-uremic syndrome in children. Int J Nephrol Renovasc Dis 2014;7:231-9. [PMID: 24966691 DOI: 10.2147/IJNRD.S41837] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]